Stockscreener 앱 받기
0.22
0.00%
0.00
시간 외 거래:
.22
Pds Biotechnology Corp 주식(PDSB)의 최신 뉴스
PDS Biotechnology’s Phase 3 Head and Neck Cancer Trial Termination: What It Means for Investors - TipRanks
PDS Biotech’s Lender Gets 100% of New Non-ATM Equity Cash - TechStock²
PDS Biotechnology Amends $6 Million Promissory Note, Tightening Repayment With YA II PN - TradingView
PDS Biotechnology (Nasdaq: PDSB) changes terms on a $6M loan - Stock Titan
Stephan Toutain removed as COO at PDS Biotechnology - TradingView
PDS Biotechnology (PDSB) to shed 36% of staff and part ways with COO - Stock Titan
PDS Biotechnology Corp (NASDAQ: PDSB) Share Price, PDSB Stock News, PDSB Share Price & Updates - Kalkine
Form 8K PDS Biotechnology Corp For: 19 August By Investing.com - Investing.com Nigeria
PDS Biotechnology announces CFO resignation and interim appointments - Investing.com
PDS Biotechnology CFO Lars Boesgaard to Resign; Janetta Trochimiuk and Frank Bedu-Addo Appointed Interim Officers - TradingView
PDS Biotechnology (NASDAQ: PDSB) CEO takes interim finance role as CFO departs - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Weekly Recap: PDS0301 Phase 2 results and Q2 adjusted loss $0.18 - TradingView
PDS Biotechnology shareholders approve charter amendment and director elections - Investing.com
Form 8K PDS Biotechnology Corp For: 14 August By Investing.com - Investing.com Nigeria
PDS Biotechnology (PDSB) wins approval to double authorized stock and elect directors - Stock Titan
PDS Biotechnology (PDSB) cuts R&D spend but warns on going concern, cash at $5.6M - Stock Titan
PDSB Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
PDS Biotechnology Q2 Results: EPS misses estimate, losses widen YoY - scanx.trade
Form 8K PDS Biotechnology Corp For: 13 August By Investing.com - Investing.com South Africa
PDS Biotechnology reports Q2 2026 net loss $9.8M, cash $5.6M, strategic refocus on PDS0301 - TradingView
PDS Biotech Reports $9.8 Million Second-Quarter 2026 Net Loss - Quiver Quantitative
PDS Biotech Reports Second Quarter 2026 Financial Results - The Manila Times
PDS Biotechnology: Q2 Earnings Snapshot - Barchart.com
PDS Biotech Prioritizes PDS0301 After 71% Response Rate In Colorectal Cancer And Discontinues PDS0101 Phase 3 Trial - Pulse 2.0
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.34% - Investing.com
PDS Biotechnology shifts focus to PDS0301, halts PDS0101 trial By Investing.com - Investing.com South Africa
PDS Biotechnology Stock Crashes, Strategic Refocus Pivots to Metastatic Colorectal Cancer Program - Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Form 8K PDS Biotechnology Corp For: 11 August By Investing.com - Investing.com Nigeria
PDS Biotech Announces Strategic Refocus Prioritizing PDS0301 in Metastatic Colorectal Cancer (mCRC) and Partnership Strategy for PDS0101 - manilatimes.net
PDS Biotechnology prioritizes PDS0301 after Phase 2 mCRC data, halts internal PDS0101 Phase 3 spend - TradingView
PDS Biotechnology shifts focus to PDS0301, halts PDS0101 trial - Investing.com
PDS Biotechnology Refocuses on PDS0301, Ends Internal Development of PDS0101 Phase 3 Trial - Quiver Quantitative
PDS0301 Data Show 80% 24-Month Survival With Liver Metastases - Stock Titan
PDS Biotechnology Corp (PDSB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
PDS Biotechnology Corp expected to post a loss of 13 cents a shareEarnings Preview - TradingView
PDS Biotechnology Corp (PDSB) Stock News Today - TradingKey
PDSB Q1 2026 Earnings: Narrower-than-Expected Loss Lifts SharesFull Year Guidance - vinanet.vn
PDS Biotechnology Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
PDSB|PDS Biotechnology Corp|Price:0.699|Chg%:+0.017 - TradingKey
PDS Biotechnology Corp (PDSB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
PDS Biotechnology Corp (PDSB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
PDS Biotechnology Corp (PDSB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
PDS Biotechnology Corp (PDSB) Balance Sheet - TradingKey
PDS Biotechnology Corp (PDSB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
PDS Biotechnology Corp (PDSB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
PDSB Q1 2026 Earnings: Narrower-than-Expected Loss and Clinical Progress Drive FocusCapex Guidance - dars.gov.et
PDSB|PDS Biotechnology Corp|Price:0.775|Chg%:+0.028 - TradingKey
TradingKey - TradingKey
PDSB|PDS Biotechnology Corp|Price:0.720|Chg%:+0.039 - TradingKey
PDS Biotechnology Corp. Revenue Breakdown – FWB:EU6 - TradingView
PDS Biotechnology Corp SEC Filing (Jul 22, 2026) - Stock Titan
Correction: Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight - GlobeNewswire Inc.
0.86%
0.31%
자본화:
|
볼륨(24시간):